TIDMVAL

RNS Number : 9971O

ValiRx PLC

06 October 2023

6 October 2023

ValiRx PLC ("ValiRx" or the "Company")

Statement re Share Price Movement

London, UK - ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women's health, notes the recent increase in the Company's share price and confirms that it is not in possession of unpublished price sensitive information.

The Company notes the announcement published by EUDA Health Holdings Limited in relation to its proposed merger with TheoremRx Inc. The announcement can be viewed in full at the link below:

https://www.globenewswire.com/news-release/2023/10/05/2755433/0/en/EUDA-Health-Holdings-Limited-Enters-into-Letter-of-Intent-for-Proposed-Merger-with-TheoremRx-Inc.html

As initially announced on 2 November 2021, VAL201, the Company's clinical asset for prostate cancer, remains subject to the Letter of Intent with TheoremRx Inc.

The Directors of the Company take responsibility for this announcement.

*** ENDS ***

For more information, please contact:

 
 ValiRx plc                                  Tel: +44 (0) 2476 796496 
                                              www.valirx.com 
  Dr Suzanne Dilly, CEO                       Suzanne.Dilly@valirx.com 
 V Formation (Public Relations)              +44 (0) 115 787 0206 
                                              www.vformation.biz 
  Lucy Wharton - Senior PR Executive 
  Sue Carr - Director                         lucy@vformation.biz 
                                              sue@vformation.biz 
                                            -------------------------- 
 Cairn Financial Advisers LLP (Nominated     Tel: +44 (0) 20 7213 
  Adviser)                                    0880 
 
  Liam Murray/ Ludovico Lazzaretti 
                                            -------------------------- 
 Cavendish Securities plc (Joint Broker)     Tel: +44 (0) 20 7397 
                                              8900 
  Dale Bellis/Michael Johnson (Sales) 
 
  Callum Davidson/Giles Balleny (Corporate 
  Finance) 
                                            -------------------------- 
 Turner Pope Investments (Joint Broker)      Tel: +44 (0) 20 3657 
  James Pope / Andy Thacker                   0050 
                                            --------------------------

Notes for Editors

About ValiRx

ValiRx is a life science company focused on early-stage cancer therapeutics and women's health, accelerating the translation of innovative science into impactful medicines to improve patient lives.

ValiRx provides the scientific, financial, and commercial framework for enabling rapid translation of innovative science into clinical development.

Using its extensive and proven experience in research and drug development, the team at ValiRx selects and incubates promising novel drug candidates and guides them through an optimised process of development, from pre-clinical studies to clinic and investor-ready assets.

ValiRx connects diverse disciplines across scientific, technical, and commercial domains, with the aim of achieving a more streamlined, less costly, drug development process. The team works closely with carefully selected collaborators and leverages the combined expertise required for science to advance.

Lead candidates from ValiRx's portfolio are outlicensed or partnered with investors through ValiRx subsidiary companies for further clinical development and commercialisation.

ValiRx listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.

For further information, visit: www.valirx.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

SPMFSESUMEDSELS

(END) Dow Jones Newswires

October 06, 2023 05:46 ET (09:46 GMT)

Grafico Azioni Valirx (LSE:VAL)
Storico
Da Apr 2024 a Mag 2024 Clicca qui per i Grafici di Valirx
Grafico Azioni Valirx (LSE:VAL)
Storico
Da Mag 2023 a Mag 2024 Clicca qui per i Grafici di Valirx